|
1）Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17
|
|
|
|
2）Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21
|
|
|
|
|
|
3）Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21
|
|
|
|
|
|
4）Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008; 168: 80-5
|
|
|
|
|
|
5）Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243-8
|
|
|
|
|
|
6）Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol. 2005; 19: 2211-21
|
|
|
|
|
|
7）Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007; 5: e012
|
|
|
|
|
|
8）Murai-Takeda A, Shibata H, Kurihara I, et al. NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. J Biol Chem. 2010; 285: 8084-93
|
|
|
|
|
|
9）Yang J, Young MJ. The mineralocorticoid receptor and its coregulators. J Mol Endocrinol. 2009; 43: 53-64
|
|
|
|
|
|
10）Yokota K, Shibata H, Kurihara I, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007; 282: 1998-2010
|
|
|
|
|
|
11）Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011; 57: 1076-80
|
|
|
|
|
|
12）Shibata H, Itoh H. Mineralocorticoid receptor-associated hyeprtension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012; 25: 514-23
|
|
|
|
|
|
13）柴田洋孝，伊藤 裕．鉱質コルチコイド受容体の転写とエピジェネティクス．最新医学．2010; 65: 79-87
|
|
|
|
|
|
14）Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011; 79: 1051-60
|
|
|
|
|
|
15）Oyamada N, Sone M, Miyashita K, et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology. 2008; 149: 3764-77
|
|
|
|
|
|
16）Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006; 147: 5363-73
|
|
|
|
|
|
17）Quinkler M, Zehnder D, Eardley KS, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005; 112: 1435-43
|
|
|
|
|
|
18）Yokota K, Shibata H, Kurihara I, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007; 282: 1998-2010
|
|
|
|
|
|
19）Kino T, Jaffe H, Amin ND, et al. Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor. Mol Endocrinol. 2010; 24: 941-52
|
|
|
|
|
|
20）Viengchareun S, Kamenicky P, Teixeira M, et al. Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line. Mol Endocirnol. 2009; 23: 1948-62
|
|
|
|
|
|
21）Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14: 1370-6
|
|
|
|
|
|
22）Shibata S, Mu SY, Kawarazaki H, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011; 121: 3233-43
|
|
|
|
|
|
23）Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000; 289: 119-23
|
|
|
|
|
|
24）Hultman ML, Krasnoperova NV, Li S, et al. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol. 2005; 19: 1460-73
|
|
|
|
|
|
25）Sechi LA, Colussi G, Di Fabio A, et al. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010; 23: 1253-60
|
|
|
|
|
|
26）Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrien Society 2009. Endocr J. 2011; 58: 711-21
|
|
|
|